Acer Therapeutics Inc. (ACER) financial statements (2020 and earlier)

Company profile

Business Address ONE GATEWAY CENTER (300 WASHINGTON ST.)
NEWTON, MA 02458
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1242163131024
Cash and cash equivalents1242163131024
Inventory, net of allowances, customer advances and progress billings      1
Inventory      1
Prepaid expense  1  00
Deferred costs     00
Other current assets   0111
Other undisclosed current assets11   (1)(1)
Total current assets:1343174141125
Noncurrent Assets
Property, plant and equipment0000111
Intangible assets, net (including goodwill)888   
Goodwill888    
Other noncurrent assets100  00
Other undisclosed noncurrent assets000    
Total noncurrent assets:9880111
TOTAL ASSETS:2151244141226
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3621222
Accounts payable1100111
Accrued liabilities2521111
Debt   00  
Deferred revenue and credits  311
Other liabilities0      
Total current liabilities:3621533
Noncurrent Liabilities
Liabilities, other than long-term debt0    12
Deferred revenue and credits   12
Other liabilities0      
Total noncurrent liabilities:0    12
Total liabilities:3621546
Stockholders' equity
Stockholders' equity attributable to parent, including:184522310721
Common stock0000000
Additional paid in capital959248164163148147
Accumulated deficit(76)(47)(26)(161)(153)(141) 
Other undisclosed stockholders' equity attributable to parent      (126)
Total stockholders' equity:184522310721
TOTAL LIABILITIES AND EQUITY:2151244141226

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues   3311
Revenue, net 3311
Cost of revenue
(Cost of Goods and Services Sold)
      (0)
Gross profit:   3311
Operating expenses(30)(22)(14)(11)(15)(16)(13)
Other undisclosed operating income (loss)     (0)0
Operating loss:(30)(22)(14)(8)(12)(15)(12)
Nonoperating income (expense)00(0)0000
Investment income, nonoperating0    00
Debt instrument, convertible, beneficial conversion feature      0
Other nonoperating income (expense) 0(0)0000
Interest and debt expense     (0)(5)
Net loss:(29)(21)(14)(8)(12)(15)(17)
Other undisclosed net income (loss) attributable to parent   00 (0)
Net loss available to common stockholders, diluted:(29)(21)(14)(8)(12)(15)(17)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(29)(21)(14)(8)(12)(15)(17)
Comprehensive loss, net of tax, attributable to parent:(29)(21)(14)(8)(12)(15)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: